Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Details 1)

v2.4.0.8
Fair Value Measurements (Details 1) (Unobservable Inputs (Level 3) [Member], USD $)
9 Months Ended
Sep. 30, 2014
Unobservable Inputs (Level 3) [Member]
 
Balance, January 1, 2014 $ 23
Change in fair value of Teva option (23)
Estimated fair value of warrants assumed in merger on January 2, 2014 10,475
Estimated fair value of warrants issued in January sale of common stock 3,696
Change of fair value of warrants for the period ended September 30, 2014 (6,929)
Balance at September 30, 2014 $ 7,242